LONDON (Reuters) - European drug regulators have recommended AstraZeneca's new thyroid cancer pill Caprelsa, or vandetanib, for approval, giving a boost to a drug which has suffered past setbacks.
Source: http://uk.reuters.com/article/2011/11/18/uk-astrazeneca-caprelsa-idUKTRE7AH0R320111118?feedType=RSS&feedName=domesticNews
restaurants science news uk news
No comments:
Post a Comment